Whole Exome Sequencing (WES) is a high-throughput, next generation sequencing-based assay analyzing the whole human exome of approximately 22,000 DNA genes.
WES is a high-throughput, next generation sequencing-based assay analyzing the whole human exome of approximately 22,000 DNA genes. Caris’ MI Exome detects DNA Point Mutations, Insertions and Deletions, Copy Number Alterations, Karyotyping, Homologous Recombination Deficiency (HRD), Genomic Loss of Heterozygosity (LOH), Microsatellite Instability (MSI), Tumor Mutational Burden (TMB) and Human Leukocyte Antigen (HLA) genotyping, all from one streamlined test. The assay integrates a 250,000 evenly-spaced genomic single nucleotide polymorphism (SNP) backbone to enhance detection of genome-level alterations, gene gain/loss and genome-wide instability.
The exons are the 1-2% of the genome that encode the proteins
Exome = Total exons of the genome
Combined with Caris MI Transcriptome Whole Transcriptome RNA Sequencing, extensive proteomic testing services, and advanced machine-learning capabilities, Caris molecular profiling is the most comprehensive and clinically relevant molecular profile for cancer patients in the industry.
*Not available in all locations.
Please complete the form below to have a Caris Scientific Rep (Medical Science Liaison) contact you directly.
"*" indicates required fields
As the pioneer in precision medicine, Caris was the first to provide comprehensive Whole Exome and Whole Transcriptome sequencing for every patient. Each Caris molecular profiling order includes next-generation sequencing of all 22,000 genes.
Looking for a specific gene? Use the full gene search below to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.
Place an order today for a comprehensive, personalized Caris profiling report.